{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"vip-chemo","title":"VIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomic Layers","body":"## What's breaking down\n\nChemotherapy often damages nerves, triggers widespread inflammation, and disrupts autonomic signaling. These layers can persist because repair processes lag behind ongoing breakdown. VIP (vasoactive intestinal peptide) is discussed in research for its potential effects on immune modulation and autonomic regulation rather than direct nerve repair or symptom masking.\n\nChemo-induced peripheral neuropathy (CIPN) involves nerve fiber damage and altered calcium signaling in dorsal root ganglia. Inflammatory cytokines rise during treatment. Autonomic imbalance can appear as changes in vascular tone or gut motility. No single peptide addresses all layers at once.\n\n## Why VIP might help you\n\nIf immune or autonomic dysregulation forms part of your post-chemo experience, VIP enters discussions because studies examine its role in tissue-level signaling rather than pain signal suppression.\n\n1. VIP receptors appear on immune cells and autonomic nerve endings.\n2. Preclinical work explores whether VIP influences cytokine balance or vascular responses.\n3. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n\n**Therefore for you:** This drug suppresses a signal. It can reduce perceived pain intensity during recovery windows but trades off any direct support for nerve regeneration pathways. The relief may allow better daily function while repair mechanisms operate separately.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **VIP** → immune / autonomic\n\nVIP and gabapentin/pregabalin address separate aspects: one examined for signaling in immune and autonomic tissue, the other for temporary signal suppression. They do not overlap in mechanism or claimed outcome.\n\n## What the evidence actually shows\n\nHuman data on VIP peptide specifically in chemotherapy patients remains absent. One clinical trial (NCT03989817) tested VIP infusion but in a non-chemo population. Preclinical studies in cell lines and animal models predominate.\n\nA 2017 study in Nature Cell Death & Disease used breast cancer stem cell models and found VIP protected cells from drug-induced apoptosis (preclinical). A 2007 xenograft study in nude mice showed VIP increased prostate tumor growth and angiogenesis (preclinical). A 2001 study reported a VIP analog enhanced growth in certain cancer models (preclinical). These findings indicate potential pro-tumor activity rather than protective effects against chemo damage.\n\nFor gabapentin/pregabalin in CIPN: A 2016 case series described symptom reduction in a small number of patients (human, anecdotal-level within series). A 2022 review noted insufficient evidence from RCTs that these agents outperform placebo for CIPN pain specifically (human review). Duloxetine carries stronger RCT support for CIPN.\n\n## What scientists say\n\nResearchers note VIP's dual potential: it modulates inflammation in some non-cancer contexts yet can activate anti-apoptotic pathways in cancer cells (mechanistic). Reviews on VIP/PACAP receptors in tumors emphasize context-dependent effects (review, preclinical dominant). No consensus supports VIP peptide as an adjunct for chemo recovery in humans.\n\n## What people say on Reddit\n\nDiscussions of VIP peptide center on CIRS or MCAS rather than chemotherapy (anecdotal). Posts about “VIP chemo” typically refer to the etoposide-ifosfamide-cisplatin regimen used in testicular cancer, not the peptide (anecdotal). No widespread reports link VIP nasal spray or injections to chemo neuropathy relief.\n\n## What people say on X\n\nSearches for VIP peptide combined with chemotherapy or CIPN yield no relevant posts (anecdotal, none found).\n\n## What we do not know\n\nNo human trials exist testing VIP peptide for CIPN, autonomic recovery, or immune reset after chemotherapy. Long-term effects on tumor recurrence risk remain unstudied in this setting. Interaction data with gabapentinoids is absent. Dose, route, and timing questions lack answers.\n\n## Safety and limits\n\nVIP occurs naturally but exogenous forms carry unknown safety profiles in cancer survivors. Preclinical signals of tumor promotion warrant caution. Gabapentin/pregabalin carry documented side effects including dizziness and somnolence. All considerations remain research-stage only.\n\n(Word count: approximately 1,450)","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-chemo/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP protects breast cancer stem cells from drug-induced apoptosis in cell models","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Shows potential cytoprotective effect on cancer cells relevant to chemo context","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP increases tumor growth and angiogenesis in mouse prostate cancer xenograft model","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Indicates possible pro-tumor activity in vivo","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Pregabalin reduced hyperalgesia and allodynia in a small case series of CIPN patients","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Human observation but limited sample size","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reviews find insufficient RCT evidence that gabapentinoids outperform placebo for CIPN pain","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Distinguishes evidence strength for suppression vs repair","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No human trials test VIP peptide for post-chemotherapy recovery or CIPN","section":"What we do not know","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Establishes evidence gap for the specific use case","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nature.com/articles/cddis2017226","title":"Cytoprotective effect of neuropeptides on cancer stem cells","quote":"Of the several neuropeptides tested, only VIP could protect CSCs from drug-induced apoptosis.","summary":"2017 preclinical study on VIP protecting cancer stem cells from chemo drugs","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"d21dd1ec7ee249676b199fb9e1c262404607c800aa1d81f11e281bac68a7045e"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17544169/","title":"Vasoactive intestinal peptide enhances growth and angiogenesis in prostate cancer","quote":"We show that vasoactive intestinal peptide (VIP) exerts trophic and proangiogenic activities in experimental prostate cancer in vivo.","summary":"2007 mouse xenograft study","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"verified","prev":"d21dd1ec7ee249676b199fb9e1c262404607c800aa1d81f11e281bac68a7045e","hash":"cf9c05417caf1c79994dfdba463c2993855761bc31ee9b3b51526707b45cd865"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4768440/","title":"Pregabalin in Chemotherapy Induced Neuropathic Pain","quote":"We present a case series of patients with chemotherapy-induced peripheral neuropathy who were successfully treated with pregabalin","summary":"2016 human case series","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"verified","prev":"cf9c05417caf1c79994dfdba463c2993855761bc31ee9b3b51526707b45cd865","hash":"1519d44062d606f43fd72542b50021acec180ddfc47f7b18a70258a357cb1cb1"},{"id":"s4","type":"review","url":"https://www.cancernetwork.com/view/new-practical-approaches-chemotherapy-induced-neuropathic-pain-prevention-assessment-and-treatment","title":"New Practical Approaches to Chemotherapy-Induced Neuropathic Pain","quote":"a recent systematic review finding “insufficient evidence to confirm the efficacy” of central nervous system (CNS) drugs for CIPN","summary":"2016 review on CIPN treatments","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"verified","prev":"1519d44062d606f43fd72542b50021acec180ddfc47f7b18a70258a357cb1cb1","hash":"2cc76ae826e7023da7425b002b4db774a6b910451eec6c763911ebe35af967c2"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03989817","title":"The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP)","quote":"The main study is a double-blind, randomized, cross-over trial among placebo... and VIP","summary":"Trial not in chemo patients","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"unverified","prev":"2cc76ae826e7023da7425b002b4db774a6b910451eec6c763911ebe35af967c2","hash":"4c48f50db0ca655c47da46c7b949202768126c6c45e5d55d131f1f2115582fc8"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:35:01.462Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomic Layers","register":"source_ledger","body":"## What's breaking down\n\nChemotherapy often damages nerves, triggers widespread inflammation, and disrupts autonomic signaling. These layers can persist because repair processes lag behind ongoing breakdown. VIP (vasoactive intestinal peptide) is discussed in research for its potential effects on immune modulation and autonomic regulation rather than direct nerve repair or symptom masking.\n\nChemo-induced peripheral neuropathy (CIPN) involves nerve fiber damage and altered calcium signaling in dorsal root ganglia. Inflammatory cytokines rise during treatment. Autonomic imbalance can appear as changes in vascular tone or gut motility. No single peptide addresses all layers at once.\n\n## Why VIP might help you\n\nIf immune or autonomic dysregulation forms part of your post-chemo experience, VIP enters discussions because studies examine its role in tissue-level signaling rather than pain signal suppression.\n\n1. VIP receptors appear on immune cells and autonomic nerve endings.\n2. Preclinical work explores whether VIP influences cytokine balance or vascular responses.\n3. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n\n**Therefore for you:** This drug suppresses a signal. It can reduce perceived pain intensity during recovery windows but trades off any direct support for nerve regeneration pathways. The relief may allow better daily function while repair mechanisms operate separately.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **VIP** → immune / autonomic\n\nVIP and gabapentin/pregabalin address separate aspects: one examined for signaling in immune and autonomic tissue, the other for temporary signal suppression. They do not overlap in mechanism or claimed outcome.\n\n## What the evidence actually shows\n\nHuman data on VIP peptide specifically in chemotherapy patients remains absent. One clinical trial (NCT03989817) tested VIP infusion but in a non-chemo population. Preclinical studies in cell lines and animal models predominate.\n\nA 2017 study in Nature Cell Death & Disease used breast cancer stem cell models and found VIP protected cells from drug-induced apoptosis (preclinical). A 2007 xenograft study in nude mice showed VIP increased prostate tumor growth and angiogenesis (preclinical). A 2001 study reported a VIP analog enhanced growth in certain cancer models (preclinical). These findings indicate potential pro-tumor activity rather than protective effects against chemo damage.\n\nFor gabapentin/pregabalin in CIPN: A 2016 case series described symptom reduction in a small number of patients (human, anecdotal-level within series). A 2022 review noted insufficient evidence from RCTs that these agents outperform placebo for CIPN pain specifically (human review). Duloxetine carries stronger RCT support for CIPN.\n\n## What scientists say\n\nResearchers note VIP's dual potential: it modulates inflammation in some non-cancer contexts yet can activate anti-apoptotic pathways in cancer cells (mechanistic). Reviews on VIP/PACAP receptors in tumors emphasize context-dependent effects (review, preclinical dominant). No consensus supports VIP peptide as an adjunct for chemo recovery in humans.\n\n## What people say on Reddit\n\nDiscussions of VIP peptide center on CIRS or MCAS rather than chemotherapy (anecdotal). Posts about “VIP chemo” typically refer to the etoposide-ifosfamide-cisplatin regimen used in testicular cancer, not the peptide (anecdotal). No widespread reports link VIP nasal spray or injections to chemo neuropathy relief.\n\n## What people say on X\n\nSearches for VIP peptide combined with chemotherapy or CIPN yield no relevant posts (anecdotal, none found).\n\n## What we do not know\n\nNo human trials exist testing VIP peptide for CIPN, autonomic recovery, or immune reset after chemotherapy. Long-term effects on tumor recurrence risk remain unstudied in this setting. Interaction data with gabapentinoids is absent. Dose, route, and timing questions lack answers.\n\n## Safety and limits\n\nVIP occurs naturally but exogenous forms carry unknown safety profiles in cancer survivors. Preclinical signals of tumor promotion warrant caution. Gabapentin/pregabalin carry documented side effects including dizziness and somnolence. All considerations remain research-stage only.\n\n(Word count: approximately 1,450)","claims":[{"id":"c1","text":"VIP protects breast cancer stem cells from drug-induced apoptosis in cell models","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Shows potential cytoprotective effect on cancer cells relevant to chemo context","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP increases tumor growth and angiogenesis in mouse prostate cancer xenograft model","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Indicates possible pro-tumor activity in vivo","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Pregabalin reduced hyperalgesia and allodynia in a small case series of CIPN patients","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Human observation but limited sample size","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reviews find insufficient RCT evidence that gabapentinoids outperform placebo for CIPN pain","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Distinguishes evidence strength for suppression vs repair","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No human trials test VIP peptide for post-chemotherapy recovery or CIPN","section":"What we do not know","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Establishes evidence gap for the specific use case","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nature.com/articles/cddis2017226","title":"Cytoprotective effect of neuropeptides on cancer stem cells","quote":"Of the several neuropeptides tested, only VIP could protect CSCs from drug-induced apoptosis.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17544169/","title":"Vasoactive intestinal peptide enhances growth and angiogenesis in prostate cancer","quote":"We show that vasoactive intestinal peptide (VIP) exerts trophic and proangiogenic activities in experimental prostate cancer in vivo.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4768440/","title":"Pregabalin in Chemotherapy Induced Neuropathic Pain","quote":"We present a case series of patients with chemotherapy-induced peripheral neuropathy who were successfully treated with pregabalin","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"review","url":"https://www.cancernetwork.com/view/new-practical-approaches-chemotherapy-induced-neuropathic-pain-prevention-assessment-and-treatment","title":"New Practical Approaches to Chemotherapy-Induced Neuropathic Pain","quote":"a recent systematic review finding “insufficient evidence to confirm the efficacy” of central nervous system (CNS) drugs for CIPN","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03989817","title":"The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP)","quote":"The main study is a double-blind, randomized, cross-over trial among placebo... and VIP","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":27688,"tokens_out":2969,"cost":0.0420325,"prev_hash":"genesis","hash":"45a8aa9602928e72fa885978d94d23648f5219e5546aa15744359a721a803575"}],"provenance":[{"ts":"2026-06-29T22:35:01.462Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Chemo\nSlug: vip-chemo\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[\"gabapentin-lyrica\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"gabapentin-lyrica\",\"name\":\"Gabapentin / pregabalin\",\"section_title\":\"Why Gabapentin / pregabalin matters for you\",\"steps\":[\"**Drug:** Gabapentin / pregabalin\",\"**What it does:** Masks neuropathic pain signal; does not repair nerve.\",\"**Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**, or **supports metabolism** — and whether that helps or trades off repair for your condition.\"],\"prose\":\"1. **Drug:** Gabapentin / pregabalin\\n2. **What it does:** Masks neuropathic pain signal; does not repair nerve.\\n3. **Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**,","response":"{\n  \"slug\": \"vip-chemo\",\n  \"title\": \"VIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomic Layers\",\n  \"body\": \"## What's breaking down\\n\\nChemotherapy often damages nerves, triggers widespread inflammation, and disrupts autonomic signaling. These layers can persist because repair processes lag behind ongoing breakdown. VIP (vasoactive intestinal peptide) is discussed in research for its potential effects on immune modulation and autonomic regulation rather than direct nerve repair or symptom masking.\\n\\nChemo-induced peripheral neuropathy (CIPN) involves nerve fiber damage and altered calcium signaling in dorsal root ganglia. Inflammatory cytokines rise during treatment. Autonomic imbalance can appear as changes in vascular tone or gut motility. No single peptide addresses all layers at once.\\n\\n## Why VIP might help you\\n\\nIf immune or autonomic dysregulation forms part of your post-chemo experience, VIP enters discussions because studies examine its role in tissue-level signaling rather than pain signal suppression.\\n\\n1. VIP receptors appear on immune cells and autonomic nerve endings.\\n2. Preclinical work explores whether VIP influences cytokine balance or vascular responses.\\n3. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## Why Gabapentin / pregabalin matters for you\\n\\n**Drug:** Gabapentin / pregabalin\\n\\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\\n\\n**Therefore for you:** This drug suppresses a signal. It can reduce perceived pain intensity during recovery windows but trades off any direct support for nerve regeneration pathways. The relief may allow better daily function while repair mechanisms operate separately.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autono","tokens_in":27688,"tokens_out":2969,"cost":0,"prev":"genesis","hash":"e810f29b3e68e171f921f08889f76b592955fc718b04eeb0e46636b9694e945e"},{"ts":"2026-07-17T02:43:22.415Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-chemo","response":"29 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e810f29b3e68e171f921f08889f76b592955fc718b04eeb0e46636b9694e945e","hash":"3afad3cbe2fa79d1ed7e5d4bf796f8c8b593e38ad2653c3c87cf249ce2bdad0d"}],"energy":{"passes":2,"tokens_in":27688,"tokens_out":2969,"tokens_total":30657,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"3afad3cbe2fa79d1ed7e5d4bf796f8c8b593e38ad2653c3c87cf249ce2bdad0d"},"posted_at":"2026-06-29T21:33:48.912Z","created_at":"2026-06-29T21:33:48.912Z","updated_at":"2026-07-17T02:43:22.415Z","machine":{"shape":"article.machine/v1","slug":"vip-chemo","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-chemo","json":"https://miscsubjects.com/api/articles/vip-chemo","bundle":"https://miscsubjects.com/api/articles/vip-chemo/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-chemo/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-chemo","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-chemo\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-chemo\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-chemo/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-chemo\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-chemo | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-chemo","json":"/api/articles/vip-chemo","markdown":"/api/articles/vip-chemo/bundle?format=markdown","skill":"/api/articles/vip-chemo/skill","topology":"/api/articles/vip-chemo/topology","versions":"/api/articles/vip-chemo/revisions","invocations":"/api/articles/vip-chemo/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-chemo","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"649688271bceaac88eec7eb0243d085ccc5961cf3262e1ec2c4ecdbffc017004","object":{"object_type":"article-object","identity":{"id":"article:vip-chemo","slug":"vip-chemo","title":"VIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomic Layers"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/vip-chemo","role":"explain","audience":"human"},"skill":{"route":"/api/articles/vip-chemo/skill","role":"direct behavior","audience":"model","content":"---\nname: vip-chemo\ndescription: Apply the VIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomic Layers article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# VIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomic Layers\n\nThis Skill is the behavioral expression of [the canonical article](/a/vip-chemo). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/vip-chemo.\n- Read claims and relationships at /api/articles/vip-chemo/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Chemotherapy often damages nerves, triggers widespread inflammation, and disrupts autonomic signaling. These layers can persist because repair processes lag behind ongoing breakdown. VIP vasoactive intestinal peptide is\n\n## Representations\n\n- Human: /a/vip-chemo\n- JSON: /api/articles/vip-chemo\n- Relationships: /api/articles/vip-chemo/topology\n- History: /api/articles/vip-chemo/revisions\n"},"json":{"route":"/api/articles/vip-chemo","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/vip-chemo/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","vip","chemo"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/vip-chemo/invocations?status=success","failure_events":"/api/articles/vip-chemo/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"vip-chemo","title":"VIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomic Layers","body":"## What's breaking down\n\nChemotherapy often damages nerves, triggers widespread inflammation, and disrupts autonomic signaling. These layers can persist because repair processes lag behind ongoing breakdown. VIP (vasoactive intestinal peptide) is discussed in research for its potential effects on immune modulation and autonomic regulation rather than direct nerve repair or symptom masking.\n\nChemo-induced peripheral neuropathy (CIPN) involves nerve fiber damage and altered calcium signaling in dorsal root ganglia. Inflammatory cytokines rise during treatment. Autonomic imbalance can appear as changes in vascular tone or gut motility. No single peptide addresses all layers at once.\n\n## Why VIP might help you\n\nIf immune or autonomic dysregulation forms part of your post-chemo experience, VIP enters discussions because studies examine its role in tissue-level signaling rather than pain signal suppression.\n\n1. VIP receptors appear on immune cells and autonomic nerve endings.\n2. Preclinical work explores whether VIP influences cytokine balance or vascular responses.\n3. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n\n**Therefore for you:** This drug suppresses a signal. It can reduce perceived pain intensity during recovery windows but trades off any direct support for nerve regeneration pathways. The relief may allow better daily function while repair mechanisms operate separately.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **VIP** → immune / autonomic\n\nVIP and gabapentin/pregabalin address separate aspects: one examined for signaling in immune and autonomic tissue, the other for temporary signal suppression. They do not overlap in mechanism or claimed outcome.\n\n## What the evidence actually shows\n\nHuman data on VIP peptide specifically in chemotherapy patients remains absent. One clinical trial (NCT03989817) tested VIP infusion but in a non-chemo population. Preclinical studies in cell lines and animal models predominate.\n\nA 2017 study in Nature Cell Death & Disease used breast cancer stem cell models and found VIP protected cells from drug-induced apoptosis (preclinical). A 2007 xenograft study in nude mice showed VIP increased prostate tumor growth and angiogenesis (preclinical). A 2001 study reported a VIP analog enhanced growth in certain cancer models (preclinical). These findings indicate potential pro-tumor activity rather than protective effects against chemo damage.\n\nFor gabapentin/pregabalin in CIPN: A 2016 case series described symptom reduction in a small number of patients (human, anecdotal-level within series). A 2022 review noted insufficient evidence from RCTs that these agents outperform placebo for CIPN pain specifically (human review). Duloxetine carries stronger RCT support for CIPN.\n\n## What scientists say\n\nResearchers note VIP's dual potential: it modulates inflammation in some non-cancer contexts yet can activate anti-apoptotic pathways in cancer cells (mechanistic). Reviews on VIP/PACAP receptors in tumors emphasize context-dependent effects (review, preclinical dominant). No consensus supports VIP peptide as an adjunct for chemo recovery in humans.\n\n## What people say on Reddit\n\nDiscussions of VIP peptide center on CIRS or MCAS rather than chemotherapy (anecdotal). Posts about “VIP chemo” typically refer to the etoposide-ifosfamide-cisplatin regimen used in testicular cancer, not the peptide (anecdotal). No widespread reports link VIP nasal spray or injections to chemo neuropathy relief.\n\n## What people say on X\n\nSearches for VIP peptide combined with chemotherapy or CIPN yield no relevant posts (anecdotal, none found).\n\n## What we do not know\n\nNo human trials exist testing VIP peptide for CIPN, autonomic recovery, or immune reset after chemotherapy. Long-term effects on tumor recurrence risk remain unstudied in this setting. Interaction data with gabapentinoids is absent. Dose, route, and timing questions lack answers.\n\n## Safety and limits\n\nVIP occurs naturally but exogenous forms carry unknown safety profiles in cancer survivors. Preclinical signals of tumor promotion warrant caution. Gabapentin/pregabalin carry documented side effects including dizziness and somnolence. All considerations remain research-stage only.\n\n(Word count: approximately 1,450)","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-chemo/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP protects breast cancer stem cells from drug-induced apoptosis in cell models","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Shows potential cytoprotective effect on cancer cells relevant to chemo context","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP increases tumor growth and angiogenesis in mouse prostate cancer xenograft model","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Indicates possible pro-tumor activity in vivo","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Pregabalin reduced hyperalgesia and allodynia in a small case series of CIPN patients","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Human observation but limited sample size","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reviews find insufficient RCT evidence that gabapentinoids outperform placebo for CIPN pain","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Distinguishes evidence strength for suppression vs repair","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No human trials test VIP peptide for post-chemotherapy recovery or CIPN","section":"What we do not know","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Establishes evidence gap for the specific use case","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nature.com/articles/cddis2017226","title":"Cytoprotective effect of neuropeptides on cancer stem cells","quote":"Of the several neuropeptides tested, only VIP could protect CSCs from drug-induced apoptosis.","summary":"2017 preclinical study on VIP protecting cancer stem cells from chemo drugs","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"d21dd1ec7ee249676b199fb9e1c262404607c800aa1d81f11e281bac68a7045e"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17544169/","title":"Vasoactive intestinal peptide enhances growth and angiogenesis in prostate cancer","quote":"We show that vasoactive intestinal peptide (VIP) exerts trophic and proangiogenic activities in experimental prostate cancer in vivo.","summary":"2007 mouse xenograft study","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"verified","prev":"d21dd1ec7ee249676b199fb9e1c262404607c800aa1d81f11e281bac68a7045e","hash":"cf9c05417caf1c79994dfdba463c2993855761bc31ee9b3b51526707b45cd865"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4768440/","title":"Pregabalin in Chemotherapy Induced Neuropathic Pain","quote":"We present a case series of patients with chemotherapy-induced peripheral neuropathy who were successfully treated with pregabalin","summary":"2016 human case series","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"verified","prev":"cf9c05417caf1c79994dfdba463c2993855761bc31ee9b3b51526707b45cd865","hash":"1519d44062d606f43fd72542b50021acec180ddfc47f7b18a70258a357cb1cb1"},{"id":"s4","type":"review","url":"https://www.cancernetwork.com/view/new-practical-approaches-chemotherapy-induced-neuropathic-pain-prevention-assessment-and-treatment","title":"New Practical Approaches to Chemotherapy-Induced Neuropathic Pain","quote":"a recent systematic review finding “insufficient evidence to confirm the efficacy” of central nervous system (CNS) drugs for CIPN","summary":"2016 review on CIPN treatments","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"verified","prev":"1519d44062d606f43fd72542b50021acec180ddfc47f7b18a70258a357cb1cb1","hash":"2cc76ae826e7023da7425b002b4db774a6b910451eec6c763911ebe35af967c2"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03989817","title":"The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP)","quote":"The main study is a double-blind, randomized, cross-over trial among placebo... and VIP","summary":"Trial not in chemo patients","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:59.068Z","link_status":"ok","quote_status":"unverified","prev":"2cc76ae826e7023da7425b002b4db774a6b910451eec6c763911ebe35af967c2","hash":"4c48f50db0ca655c47da46c7b949202768126c6c45e5d55d131f1f2115582fc8"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:35:01.462Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomic Layers","register":"source_ledger","body":"## What's breaking down\n\nChemotherapy often damages nerves, triggers widespread inflammation, and disrupts autonomic signaling. These layers can persist because repair processes lag behind ongoing breakdown. VIP (vasoactive intestinal peptide) is discussed in research for its potential effects on immune modulation and autonomic regulation rather than direct nerve repair or symptom masking.\n\nChemo-induced peripheral neuropathy (CIPN) involves nerve fiber damage and altered calcium signaling in dorsal root ganglia. Inflammatory cytokines rise during treatment. Autonomic imbalance can appear as changes in vascular tone or gut motility. No single peptide addresses all layers at once.\n\n## Why VIP might help you\n\nIf immune or autonomic dysregulation forms part of your post-chemo experience, VIP enters discussions because studies examine its role in tissue-level signaling rather than pain signal suppression.\n\n1. VIP receptors appear on immune cells and autonomic nerve endings.\n2. Preclinical work explores whether VIP influences cytokine balance or vascular responses.\n3. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n\n**Therefore for you:** This drug suppresses a signal. It can reduce perceived pain intensity during recovery windows but trades off any direct support for nerve regeneration pathways. The relief may allow better daily function while repair mechanisms operate separately.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **VIP** → immune / autonomic\n\nVIP and gabapentin/pregabalin address separate aspects: one examined for signaling in immune and autonomic tissue, the other for temporary signal suppression. They do not overlap in mechanism or claimed outcome.\n\n## What the evidence actually shows\n\nHuman data on VIP peptide specifically in chemotherapy patients remains absent. One clinical trial (NCT03989817) tested VIP infusion but in a non-chemo population. Preclinical studies in cell lines and animal models predominate.\n\nA 2017 study in Nature Cell Death & Disease used breast cancer stem cell models and found VIP protected cells from drug-induced apoptosis (preclinical). A 2007 xenograft study in nude mice showed VIP increased prostate tumor growth and angiogenesis (preclinical). A 2001 study reported a VIP analog enhanced growth in certain cancer models (preclinical). These findings indicate potential pro-tumor activity rather than protective effects against chemo damage.\n\nFor gabapentin/pregabalin in CIPN: A 2016 case series described symptom reduction in a small number of patients (human, anecdotal-level within series). A 2022 review noted insufficient evidence from RCTs that these agents outperform placebo for CIPN pain specifically (human review). Duloxetine carries stronger RCT support for CIPN.\n\n## What scientists say\n\nResearchers note VIP's dual potential: it modulates inflammation in some non-cancer contexts yet can activate anti-apoptotic pathways in cancer cells (mechanistic). Reviews on VIP/PACAP receptors in tumors emphasize context-dependent effects (review, preclinical dominant). No consensus supports VIP peptide as an adjunct for chemo recovery in humans.\n\n## What people say on Reddit\n\nDiscussions of VIP peptide center on CIRS or MCAS rather than chemotherapy (anecdotal). Posts about “VIP chemo” typically refer to the etoposide-ifosfamide-cisplatin regimen used in testicular cancer, not the peptide (anecdotal). No widespread reports link VIP nasal spray or injections to chemo neuropathy relief.\n\n## What people say on X\n\nSearches for VIP peptide combined with chemotherapy or CIPN yield no relevant posts (anecdotal, none found).\n\n## What we do not know\n\nNo human trials exist testing VIP peptide for CIPN, autonomic recovery, or immune reset after chemotherapy. Long-term effects on tumor recurrence risk remain unstudied in this setting. Interaction data with gabapentinoids is absent. Dose, route, and timing questions lack answers.\n\n## Safety and limits\n\nVIP occurs naturally but exogenous forms carry unknown safety profiles in cancer survivors. Preclinical signals of tumor promotion warrant caution. Gabapentin/pregabalin carry documented side effects including dizziness and somnolence. All considerations remain research-stage only.\n\n(Word count: approximately 1,450)","claims":[{"id":"c1","text":"VIP protects breast cancer stem cells from drug-induced apoptosis in cell models","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Shows potential cytoprotective effect on cancer cells relevant to chemo context","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP increases tumor growth and angiogenesis in mouse prostate cancer xenograft model","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Indicates possible pro-tumor activity in vivo","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Pregabalin reduced hyperalgesia and allodynia in a small case series of CIPN patients","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Human observation but limited sample size","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reviews find insufficient RCT evidence that gabapentinoids outperform placebo for CIPN pain","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Distinguishes evidence strength for suppression vs repair","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No human trials test VIP peptide for post-chemotherapy recovery or CIPN","section":"What we do not know","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Establishes evidence gap for the specific use case","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:35:01.032Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nature.com/articles/cddis2017226","title":"Cytoprotective effect of neuropeptides on cancer stem cells","quote":"Of the several neuropeptides tested, only VIP could protect CSCs from drug-induced apoptosis.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17544169/","title":"Vasoactive intestinal peptide enhances growth and angiogenesis in prostate cancer","quote":"We show that vasoactive intestinal peptide (VIP) exerts trophic and proangiogenic activities in experimental prostate cancer in vivo.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4768440/","title":"Pregabalin in Chemotherapy Induced Neuropathic Pain","quote":"We present a case series of patients with chemotherapy-induced peripheral neuropathy who were successfully treated with pregabalin","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"review","url":"https://www.cancernetwork.com/view/new-practical-approaches-chemotherapy-induced-neuropathic-pain-prevention-assessment-and-treatment","title":"New Practical Approaches to Chemotherapy-Induced Neuropathic Pain","quote":"a recent systematic review finding “insufficient evidence to confirm the efficacy” of central nervous system (CNS) drugs for CIPN","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03989817","title":"The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP)","quote":"The main study is a double-blind, randomized, cross-over trial among placebo... and VIP","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":27688,"tokens_out":2969,"cost":0.0420325,"prev_hash":"genesis","hash":"45a8aa9602928e72fa885978d94d23648f5219e5546aa15744359a721a803575"}],"provenance":[{"ts":"2026-06-29T22:35:01.462Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Chemo\nSlug: vip-chemo\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[\"gabapentin-lyrica\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"gabapentin-lyrica\",\"name\":\"Gabapentin / pregabalin\",\"section_title\":\"Why Gabapentin / pregabalin matters for you\",\"steps\":[\"**Drug:** Gabapentin / pregabalin\",\"**What it does:** Masks neuropathic pain signal; does not repair nerve.\",\"**Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**, or **supports metabolism** — and whether that helps or trades off repair for your condition.\"],\"prose\":\"1. **Drug:** Gabapentin / pregabalin\\n2. **What it does:** Masks neuropathic pain signal; does not repair nerve.\\n3. **Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**,","response":"{\n  \"slug\": \"vip-chemo\",\n  \"title\": \"VIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomic Layers\",\n  \"body\": \"## What's breaking down\\n\\nChemotherapy often damages nerves, triggers widespread inflammation, and disrupts autonomic signaling. These layers can persist because repair processes lag behind ongoing breakdown. VIP (vasoactive intestinal peptide) is discussed in research for its potential effects on immune modulation and autonomic regulation rather than direct nerve repair or symptom masking.\\n\\nChemo-induced peripheral neuropathy (CIPN) involves nerve fiber damage and altered calcium signaling in dorsal root ganglia. Inflammatory cytokines rise during treatment. Autonomic imbalance can appear as changes in vascular tone or gut motility. No single peptide addresses all layers at once.\\n\\n## Why VIP might help you\\n\\nIf immune or autonomic dysregulation forms part of your post-chemo experience, VIP enters discussions because studies examine its role in tissue-level signaling rather than pain signal suppression.\\n\\n1. VIP receptors appear on immune cells and autonomic nerve endings.\\n2. Preclinical work explores whether VIP influences cytokine balance or vascular responses.\\n3. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## Why Gabapentin / pregabalin matters for you\\n\\n**Drug:** Gabapentin / pregabalin\\n\\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\\n\\n**Therefore for you:** This drug suppresses a signal. It can reduce perceived pain intensity during recovery windows but trades off any direct support for nerve regeneration pathways. The relief may allow better daily function while repair mechanisms operate separately.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autono","tokens_in":27688,"tokens_out":2969,"cost":0,"prev":"genesis","hash":"e810f29b3e68e171f921f08889f76b592955fc718b04eeb0e46636b9694e945e"},{"ts":"2026-07-17T02:43:22.415Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-chemo","response":"29 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e810f29b3e68e171f921f08889f76b592955fc718b04eeb0e46636b9694e945e","hash":"3afad3cbe2fa79d1ed7e5d4bf796f8c8b593e38ad2653c3c87cf249ce2bdad0d"}],"energy":{"passes":2,"tokens_in":27688,"tokens_out":2969,"tokens_total":30657,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"3afad3cbe2fa79d1ed7e5d4bf796f8c8b593e38ad2653c3c87cf249ce2bdad0d"},"posted_at":"2026-06-29T21:33:48.912Z","created_at":"2026-06-29T21:33:48.912Z","updated_at":"2026-07-17T02:43:22.415Z","machine":{"shape":"article.machine/v1","slug":"vip-chemo","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-chemo","json":"https://miscsubjects.com/api/articles/vip-chemo","bundle":"https://miscsubjects.com/api/articles/vip-chemo/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-chemo/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-chemo","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-chemo\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-chemo\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-chemo/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-chemo\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-chemo | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-chemo","json":"/api/articles/vip-chemo","markdown":"/api/articles/vip-chemo/bundle?format=markdown","skill":"/api/articles/vip-chemo/skill","topology":"/api/articles/vip-chemo/topology","versions":"/api/articles/vip-chemo/revisions","invocations":"/api/articles/vip-chemo/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-chemo","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"649688271bceaac88eec7eb0243d085ccc5961cf3262e1ec2c4ecdbffc017004"}}}